Antiangiogenic drugs in ovarian cancer

Abstract

Background: There is a critical need to develop effective new strategies for the management of patients with advanced epithelial ovarian cancer. Objective: The purpose of this manuscript is to discuss the rationale for, and initial clinical results of, attempts to interfere with the process of tumor angiogenesis as a novel treatment paradigm in ovarian cancer. Results/ conclusion: Phase II clinical trial data provide strong support for the suggestion that antiangiogenic agents have the potential to play a major therapeutic role in this difficult malignancy. It is reasonable to acknowledge that the pending results of several ongoing evidence-based randomized Phase III trials that directly explore the clinical utility of this strategy may substantially alter the current standard management approaches in advanced ovarian cancer.

Keywords::

• angiogenesis
• antiangiogenic agents
• bevacizumab
• cancer chemotherapy
• ovarian cancer